Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.

"This paves the way for a new phase in Qlucore's development. With the funding from the rights issue in conjunction with this listing Qlucore now has the resources to launch its software globally and create conditions for better cancer care, with fast and precise large data set analysis" says Pia Gideon, Chairman of the Board at Qlucore.

Qlucore has, as earlier communicated, concluded a rights issue to public and professional investors, both in Sweden and internationally, for a total of approximately 9.1 million EURO. The rights issue was fully subscribed. At the time of the rights issue it was also communicated that Qlucore had the intention to list shares on Nasdaq First North Growth Market. Qlucore has today received this approval.

The first day of trading is November 5, 2021. The share will be traded with the ticker QCORE, and the ISIN-code is SE0016829824.

For further information please contact:

Carl-Johan Ivarsson, CEO Qlucore
Phone: +46 46 286 3110, email: carl-johan.ivarsson@qlucore.com
Web: www.qlucore.com

Otto Rydbeck, CEO Stockholm Corporate Finance
Phone: +46 708 78 48 70, email: otto.rydbeck@stockholmcorp.se
Web: www.stockholmcorp.se

This information was provided through the above contact persons action for the public November 4 2021 at 14.00 CEST.

Advisors

Stockholm Corporate Finance acted as financial advisor and Advokatfirman Lindahl acted as legal advisors to Qlucore. Hagberg & Aneborn Fondkommission was the issuing agent. 

Certified Adviser

FNCA Sweden AB
Telefon: +46 8 528 003 99, e-post: info@fnca.se
Web: www.fnca.se

About Qlucore AB

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a Do-It-Yourself bioinformatics software for research in the life science, plant and biotech industries, as well as academia. Qlucore Diagnostics and Qlucore Insight are software platforms with built-in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 at Lund University, Sweden and has today customers in about 25 countries around the world, sales offices in Europe and North America, and distribution in several countries in Asia. www.qlucore.com

About Stockholm Corporate Finance AB

Stockholm Corporate Finance is an independent privately owned financial advisor that offers services within qualified advice regarding capital raising, changes of ownership, mergers and acquisitions (M&A) to listed and private companies and their owners. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which consists of 49 M&A advisers and investment banks in 36 countries. Stockholm Corporate Finance is an investment firm under the supervision of Financial Supervisory Authority (Swe: Finansinspektionen) and is a member of the industry association SwedSec Licensiering AB.
www.stockholmcorp.se

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe", “expect", “anticipate", “intend", “may", “plan", “estimate", “will", “should", “could", “aim" or “might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.